Carcinoma, Transitional Cell

23 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Carcinoma, Neoplasms

Treatments and conditions

Carcinoma, Transitional Cell
Treatment and conditionWhere it standsTrials
ASP2998 for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ASP2998 + Carboplatin + ENFORTUMAB VEDOTIN + PEMBROLIZUMAB for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Avelumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enfortumab vedotin + pembrolizumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ERDAFITINIB + Carboplatin + CETRELIMAB + CISPLATIN for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Erdafitinib + cetrelimab for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Izalontamab Brengitecan for carcinoma, transitional cellPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Pharmacological Study + Eribulin Mesylate for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
n-dodecyl-B-D-maltoside + Cretostimogene Grenadenorepvec for carcinoma, transitional cellPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed + AVELUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PF-08634404 for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
PF-08634404 + ENFORTUMAB VEDOTIN for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Reproductive organ sparing radical cystectomy for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab tirumotecan for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SI-B003 + Izalontamab Brengitecan for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TTP-ICG fluorescent probe for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TYRA-300 for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.